The biotech firm is currently testing its primary drug candidate, BBT001, in clinical trials across the U.S., Australia, Europe, and New Zealand to treat moderate-to-severe atopic dermatitis. Simultaneously, the company has launched a Phase 2a trial in China targeting chronic spontaneous urticaria. These efforts are backed by principal stockholders including Salvia Investment and affiliates of RA Capital and Biotechnology Value Fund.

Despite these developments, the company remains in the pre-revenue stage. Bambusa has yet to disclose the intended size of its offering or a target price range for its shares, leaving investors to await further filings regarding the valuation of its specialized immunology assets.